 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Questcor Pharmaceuticals, Inc.
 |
Questcor Pharmaceuticals, Inc. |
 |
 |
 |
PROFILE |
 |
Questcor Pharmaceuticals is questing for new drugs. The firm develops drugs for use in hospitals. Its primary products are Glofil and Inulin, intravenous drugs that assess kidney functions, and Ethamolin, which treats esophageal bleeding associated with liver disease and hypertension. Drugs in development include Cordox, a sickle cell anemia treatment, and Emitasol, a treatment for diabetic gastroparesis. It also has a focus on ischemic disorders, developing therapies for closed head injuries and other conditions. Questcor took a hit when client NutraMax Products, for whom it manufactured its Neoflo technology for NutraMax's bandages, filed for bankruptcy.
COMPETITION |
 |
Boston Scientific Corporation (BSX)
Mallinckrodt Inc. (dossier)
Sanofi-Synthélabo (SAN)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 1.20
1-Yr. Sales Growth: 20.0%
KEY PEOPLE |
 |
Charles J. Casamento
CEO
Hans P. Schmid
CFO
CONTACT INFO |
 |
26118 Research Rd.
Hayward, CA 94545
US
Phone: 510-732-5551
Fax: 510-732-7741
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |